We have previously shown that metastasis-associated protein 1 (MTA1), a chromatin remodeler, plays an important role in prostate cancer invasiveness, likely through regulation of epithelial-to-mesenchymal transition. Here, we identified miR-22 as an epigenetic-microRNA (Epi-miR) directly induced by MTA1 and predicted to target E-cadherin. Loss-of-function and overexpression studies of MTA1 reinforced its regulatory role in miR-22 expression. MiR-22 directly targets the 3 0 -untranslated region of E-cadherin, and ectopic overexpression of miR-22 diminishes E-cadherin expression. Overexpression of miR-22 in prostate cancer cells promotes cell invasiveness and migration. Meta-analysis of patient tumor samples indicates a positive correlation between MTA1 and miR-22, supporting their inhibitory effect on E-cadherin expression. Our findings implicate the MTA1/Epi-miR-22/E-cadherin axis as a new epigenetic signaling pathway that promotes tumor invasion in prostate cancer.
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Keywords: E-cadherin; miR-22; MTA1; prostate cancer About one in seven American men will be diagnosed with prostate cancer. Front-line treatment options for the individuals with high-risk localized or advanced disease include radical prostatectomy, radiotherapy and androgen deprivation therapies [1] [2] [3] . However, in lack of novel treatment options, the patients regularly relapse with the more invasive resistance disease resulting in high mortality [1, 4] .
Epithelial-to-mesenchymal transition (EMT) is a fundamental pathological change responsible for the establishment of invasive phenotype by tumor cells [5] [6] [7] . E-cadherin, a transmembrane glycoprotein that plays a critical role in maintaining adherens junctions, when downregulated or inactivated in epithelial cells leads to acquisition of mesenchymal characteristics, thus promoting EMT [8] [9] [10] . Although much is known about the EMT pathway, critical upstream regulators in the process have yet to be identified.
Epigenetic factors, including chromatin remodelers and microRNAs (miRs) have emerged as critical regulators of genes involved in EMT and prostate cancer invasiveness [11] [12] [13] [14] [15] . Moreover, there is a feedback regulation between epigenetic factors and miRNAs themselves that can decide the fate of gene expression. These miRNAs that are regulated by or are regulating Abbreviations ChIP-Seq, Chromatin Immunoprecipitation Sequencing; E-cad, E-cadherin; EV, empty vector; INH, inhibitor; MIM, mimic; Pb, probasin; UTR, untranslated region.
epigenetic factors, such as HDAC and HAT [16] [17] [18] , are called 'Epi-miRs' [19, 20] .
MTA1, an epigenetic reader, is overexpressed in highly invasive metastatic prostate cancer [21] [22] [23] [24] . We have reported the functional importance of MTA1 in prostate cancer progression in both in vitro and in vivo studies [15, [24] [25] [26] [27] [28] . One of the proinvasive and prometastatic pathways regulated by MTA1 is regulation of Ecadherin [27, 29, 30] . In addition, our ChIP-Seq studies identified Epi-miRNAs directly regulated by MTA1 (A. Kumar, S. Dhar and A. S. Levenson, unpublished data). Therefore, we hypothesized that MTA1-promoted prostate cancer invasiveness may include the Epi-miRmediated regulation of E-cadherin and EMT phenotype.
In this study, we demonstrate that miR-22 is induced by MTA1 and that MTA1-associated repression of Ecadherin is mediated, at least in part, through EpimiR-22. We show that miR-22 directly targets 3 0 -untranslated region (UTR) of E-cadherin and that overexpression of MTA1 or miR-22 decreases E-cadherin while depletion of MTA1 or miR-22 restores Ecadherin levels. We also demonstrate that ectopic overexpression of miR-22 results in enhanced invasiveness and migration of prostate cancer cells. Human prostate tumor samples also demonstrate positive correlation between MTA1 and miR-22 expression and their inverse correlation with E-cadherin levels. Collectively, our studies reveal a new Epi-miR-mediated proinvasive pathway in prostate cancer, downstream of MTA1.
Materials and methods

Cell culture, animal and clinical studies
Prostate cancer cell lines LNCaP, DU145, 22Rv1 and PC3M (ATCC, Manassas, VA, USA) were maintained in RPMI1640 and 10% fetal bovine serum, while RWPE-1 was maintained on keratinocyte serum free medium with epidermal growth factor (EGF) and bovine pituitary extract as supplements as per manufacturer's instructions with added 1% Anti-Anti (Thermo Fisher Scientific, Waltham, MA, USA) at 37°C, 5% CO 2 . Cell lines were authenticated by short tandem repeat (STR) profiling and were certified free of mycoplasma contamination (mycoplasma detection kit; ATCC). All animal studies were approved by the Institutional Animal Ethics Committee (Protocol#1272A). For clinical studies, upon approval of the study from the Institutional Review Board, fresh prostatectomy specimens were obtained immediately after surgery. The information on grade and location of the tumor was known based on previous prostate biopsies and imaging studies wherever available. The areas of firm nodularity and correlation with previous biopsy results were the sites from where the pathologists took core needle biopsies under sterile conditions, using Coaxial Achieve Automatic Biopsy System (14G 9 11 cm). The cores on an average measured between 0.5 cm up to 1.3 cm in length and 1-1.5 mm in diameter. Immediate touch-imprints for cytological examination were taken followed by Diff Quik and/or H&E staining. Subsequently, the biopsy specimens were aseptically collected in vials and snap frozen for further processing either for RNA or protein analysis. For RNA, one biopsy per sample was used, whereas for protein analysis, 2-3 core biopsies were pooled to extract protein. Only those biopsies were analyzed in which the pathologists suspected the tumor to be present based on touch imprint cytology. 
Cell transfections
Quantitative real-time PCR
RNA was isolated from cell lines using a miRNeasy Mini Kit (Qiagen, Hilden, Germany) as per manufacturer's instructions. Real-time PCR was performed using a miRCURY LNA TM Universal RT microRNA PCR kit (Exiqon) and custom primers specific for hsa-miR-22-3p were used. SNORD44 and U6 (Exiqon) were used as internal references except for mouse tissue samples where miR-103a-3p was used as an internal reference. For E-cadherin and MTA1 mRNA expression, RNA was reverse transcribed using the two-step RT-PCR kit with random primers (Thermo Fisher Scientific) and qRT-PCR was performed using 2 9 SYBR green mix (Thermo Fisher Scientific). Fold changes in miRNA or mRNA expression were estimated by the 2 ÀDDCt method.
Immunoblotting
Cell lysates were prepared using RIPA buffer and phosphatase and protease INHs as per manufacturer's instructions (Thermo Fisher Scientific). Seventy microgram protein was loaded on 10% Tris-glycine-SDS gels and proteins transferred to poly(vinylidene difluoride) (PVDF) membrane. The membranes were probed with E-cadherin (1 : 1000; Cell Signaling, Danvers, MA, USA), MTA1 (1 : 1000; Cell Signaling) and b-actin antibodies (1 : 2500; Santa Cruz Biotechnologies, Dallas, TX, USA). Signals were visualized using the SuperSignal West Dura chemiluminescence kit (Thermo Fisher Scientific) and imaged on a Chemidoc gel imager (Bio-Rad, Hercules, CA, USA). Images were quantified using the IMAGE J software (NIH, Bethesda, MD, USA).
Immunohistochemistry
Tissue paraffin embedding, sectioning (4 lm) and H&E staining were performed by Reveal Biosciences (San Diego, CA, USA). Briefly, sections were deparaffinized, rehydrated with xylene and descending grades of alcohol and water. Antigen retrieval was performed by boiling the slides in Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA, USA) for 30 min in a steamer. Slides were cooled and endogenous peroxidase activity was quenched in 3% H 2 O 2 in ethanol for 5 min. Blocking was performed in accordance with the appropriate antibodies employed for staining using the Vectastain ABC Elite Kit (Vector Laboratories). Sections were stained overnight using antibodies against E-cadherin (1 : 400; Cell Signaling Technologies) and MTA1 (1 : 50; Cell Signaling Technologies). DAB staining was performed using the Vectastain ABC Elite kit and ImmPACT DAB kit (Vector Laboratories) and images were captured using the Nikon Eclipse 80i microscope (Nikon Instruments Inc., Melville, NY, USA).
Dual luciferase assay
A 487 bp fragment of the CDH1/E-cadherin 3 0 -UTR covering the miR-22 seed sequence (GGCAGCT) was cloned in the Sac I (New England Biolabs, Ipswich, MA, USA) site of the pMIRGLO vector (Promega) after the Firefly luciferase gene, using the InFusion HD cloning kit (Clontech, Mountain View, CA, USA) and primer sequences Forward 5ʹ-CTAGTTGTTTAAACGAGCTCACAGATGGGGTCTT GCTAT-3ʹ and Reverse 5ʹ-GACTCGAGGCTAGCGAG CTCTCAATGACAAGCTCTCCTG-3ʹ. Point mutations at three sites in the seed sequence (GACCGAT, in bold, see Fig. 2a ) were introduced following the InFusion Mutagenesis method (Clontech) and mutant primers forward 5ʹ-CTGGATATCGGTCCATTGCAAGTT-3ʹ and reverse 5ʹ-GCAATGGACCGATATCCAGTGACT-3ʹ. The orientation of the insert was verified by sequencing (Eton Biosciences, San Diego, CA, USA 
Invasion and wound healing assays
Cell invasion assays were performed using BD BioCoat matrigel coated transwells with 8 lm polyethyleneterepthalate membrane (Corning Life Sciences). The transwells were conditioned in 100 lL serum-free medium for 2 h at 37°C, 5% CO 2 . Cells (10 9 10 4 ) were seeded carefully on the transwells in 0.5 mL serum-free medium while the bottom half was filled with complete medium (10% FBS) as chemoattractant and incubated for 48 h. After the incubation, cells in the upper membrane was scraped off with a cotton tip and the membrane was taken out gently, fixed in methanol for 10 min, stained with 1% crystal violet and mounted on a glass slide. Images were recorded on a Nikon Eclipse 80i microscope (magnification 9 100) (Nikon Instruments Inc). Motility changes in miR-22 overexpressing cells were determined by the wound healing assay. Briefly, cells were grown to 80% confluence in six-well plates, transfected with miR-22 MIM and after 24 h, three vertical scratches were made with a sterile 200 lL pipette across the well. The cells were washed with PBS and maintained in serumfree medium. Images were recorded at 0, 24, 48 and 96 h on an Olympus CKX41 microscope with U-CMAD3 camera using the INFINITY ANALYZE software (version 5.0.3; Lumera Corporation, Bothell, WA, USA). The width of the scratch were measured using the IMAGE J (NIH, Bethesda, MD, USA) software and percentage healing was calculated (magnification 9 40).
ChIP-Seq analysis
Pten +/f mouse prostates were isolated as described previously [27] and 200 mg of tissue was used to perform ChIPSeq with MTA1 Ab (Bethyl Laboratories, Montgomery, TX, USA; A300-911A, 4 lg) at active motif (Carlsbad, CA, USA). Reads were aligned to the mouse genome (mm 10). Peak calling was performed using the SICER algorithm at a cutoff of FDR1E-10. The numbers of peaks identified was about 38 000 and 33 000 for MTA1 (Ctrl and PTER, respectively). The ChIP-Seq profiles presented were generated using the UCSC Genome browser.
cBIOPortal analysis MIR-22, MTA1 and CDH1 were queried across various prostate cancer databases for mRNA expression, and coexpression and alteration frequencies were reported using cBIOPortal (http://www.cbioportal.org/index.do).
Statistical analyses
The difference between groups was analyzed by the twosample two-tailed Student's t test. Statistical significance was set as P ≤ 0.05. All data are cumulative of at least three independent experiments.
Results
MTA1 and miR-22 negatively regulate E-cadherin
Our miRNA microarray profiling study identified a group of candidate oncogenic and tumor supressive epi-miRNAs regulated by MTA1 in prostate cancer (Fig. 1A) . Of the identified candidates, the onco-EpimiRNA miR-22 was of particular interest to us because of its substantially decreased levels in the LNCaP cells silenced for MTA1 (shMTA1) (Fig. 1A) , its known high expression and oncogenic role in prostate cancer [11] , and its predicted targeting of E-cadherin (CDH1) 3 0 -UTR by at least three available algorithms (miRanda, miRDB and TargetScan v 7.0). We confirmed miR-22 association with MTA1 in a screen of prostate cancer cell lines, where aggressive cells, DU145 and PC3M, with high MTA1, had highest miR-22 levels compared to RWPE1 and LNCaP cells [23] (Fig. S1A,B) . Concurrently, E-cadherin was lowest in the most aggressive prostate cancer cells (Fig. S1C,D) . To further validate the relationship between MTA1/miR-22/E-cadherin, we examined miR-22 expression in LNCaP and DU145 cells silenced for MTA1, and found a significant reduction in miR-22 levels (Fig. 1B) with a concomitant increase in E-cadherin expression [27] (Fig. 1C) .
Prostate-specific overexpression of MTA1 transgene in mice led to increased expression of miR-22 while Ecadherin expression was significantly compromised (Fig. 1D-F) . Moreover, our ChIP-Seq studies with pharmacological inhibition of MTA1 by pterostilbene revealed decreased MTA1 occupancy onto the miR-22 promoter (Fig. S1E) . Taken together, our data support a putative role for MTA1-miR-22-dependent regulation of E-cadherin expression (Fig. 1G ) in addition to the already reported direct regulation of E-cadherin by MTA1 [27, 29, 30] .
MiR-22 targets the 3 0 -UTR of E-cadherin
According to miRanda, miRDB and TargetScan v 7.0, miR-22 has a single predicted target site in the Ecadherin 3 0 -UTR ( Fig. 2A, top) . Using a 3 0 -UTR dual luciferase reporter assay system, we found that the coexpression of miR-22 using miRNA MIM with wild-type 3 0 -UTR but not with mutant 3 0 -UTR in LNCaP and RWPE1 cells significantly suppressed the luciferase activity ( Fig. 2A, bottom) , indicating that miR-22 directly targets the E-cadherin 3 0 -UTR. Further, we overexpressed miR-22 in LNCaP and RWPE1 cells and also depleted miR-22 in PC3M and DU145 cells using miRNA INHs, and found significant downregulation of E-cadherin mRNA and protein levels in LNCaP (Fig. 2B-D) and RWPE1 (Fig. S2A,B ) cells overexpressing miR-22. In contrast, PC3M cells with miR-22 depletion exhibited a significant upregulation of E-cadherin mRNA and protein levels (Fig. 2E,F) , which were mirrored in DU145 cells (Fig. S2C) . Thus, we concluded that miR-22 directly targets the E-cadherin 3 0 -UTR and regulates its mRNA and protein expression. Interestingly, ectopic overexpression of miR-22 in LNCaP cells silenced for MTA1 (shMTA1) led to significant downregulation of the elevated E-cadherin mRNA (Fig. 2G) , reiterating that miR-22 targets E-cadherin and that MTA1-dependent E-cadherin repression in prostate cancer is mediated, at least in part, through regulation of miR-22.
Mir-22 overexpression enhances invasion and wound healing properties of PCa cells
To determine the functional consequence of miR-22-mediated downregulation of E-cadherin in prostate cancer, we ectopically overexpressed miR-22 in RWPE1 and LNCaP cells and observed their invasive and migratory capacity. We detected a significant increase in invasion (Fig. 3A,B ) and wound closure (Fig. 3C,D) in both cells lines with the effects being more significant in RWPE1 cells. Thus, miR-22 promotes invasion and migration in prostate cancer cells.
MTA1 and miR-22 expression correlate strongly in prostate cancer clinical samples
To explore the clinical significance of the MTA1/miR-22/E-cad inter-relationship in prostate cancer, we determined the expression of MTA1, miR-22 and E-cadherin in a cohort of 10 prostate adenocarcinoma biopsies. On the mRNA levels, we found a positive correlation between MTA1 and miR-22 (r = 0.35) and a negative correlation between miR-22 and E-cadherin expression (r = À0.27) (Fig. 4A) . Using additional eight prostate adenocarcinoma biopsies, which include three biopsies from the previous cohort (# 1, 2, 7), we found positive correlation between miR-22 expression and MTA1 protein levels, and negative correlation between miR-22 expression and E-cadherin protein levels in aforementioned three samples (#1, 2, 7) (Fig. 4B) . Accordingly, a strong negative correlation between MTA1 and E-cadherin protein levels was observed: about 67% of the biopsies with high MTA1 had low E-cadherin and about 60% of the biopsies with low MTA1 had high E-cadherin expression (Fig. 4B, bottom, C) . To strengthen our findings from smaller sample numbers, we interrogated the TCGA database to determine the relationship between MTA1/miR-22/E-cad. MTA1 and CDH1 (E-cadherin) showed a negative correlation in our in silico study ( Fig. 4D , r = À0.38) from 333 patient samples [31] accessible from cBioPortal for Cancer Genomics [32, 33] . In addition, copy number analysis (CNA) data of the prostate cancer patient samples from independent studies showed an amplification of MTA1 and miR-22 with a deletion of E-cadherin (Fig. S3) . Taken together, studies indicate that E-cadherin is downregulated in prostate tumors and that this may depend, at least in part, on the MTA1-associated induction of miR-22.
Discussion
Epigenetic factors, such as chromatin remodelers and miRs, play substantial role in determining the progression of prostate cancer to metastasis. Owing to the very complex epigenetic regulatory network that guides miR expression and activity, the role of miR-22 in cancer is contradictory. Accordingly, miR-22 has been reported as a tumor suppressor [34] [35] [36] [37] [38] [39] [40] [41] and sometimes as an oncogene [5, 11, 42] , depending on the diverse cancer types and the exact functions of their target genes. In agreement with Pandolfi's group, we identified miR-22 as belonging to the class of EpimiRs and as a regulator of EMT [5] . Importantly, the same group convincingly demonstrated the direct targeting of PTEN tumor suppressor by miR-22 in prostate cancer [11] . We too, validated downregulation of PTEN protein levels in RWPE1 cells transfected with miR-22 MIMs (Fig. S2B) . Thus, our current study supports the oncogenic nature of miR-22 in prostate cancer as reported by others. The fact that in prostate cancer, miR expression correlates with Gleason score and clinical recurrence [12, 13, 43, 44] and that miRs can be easily detected in plasma [12, [45] [46] [47] signifies the utilization of miR-regulated pathways as potential prognostic biomarkers for aggressive disease. MTA1-activated Epi-miR-22 and E-cad levels from expression array [31] using the cBioPortal for Cancer Genomics [32, 33] .
regulation of adhesion factor E-cadherin, whose role in invasion and metastasis has been demonstrated in vitro and in vivo [9, 10, [48] [49] [50] [51] [52] makes this signaling axis critical for promoting the acquisition of invasive phenotype by prostate tumor cells, and therefore, a strong potential target for novel therapeutic options against invasive prostate cancer. In summary, we identified the MTA1/miR-22/E-cad axis as a novel pathway contributing to the MTA1-driven invasiveness in prostate cancer. Our study warrants further investigation to validate Epi-miR-22 as a prognostic biomarker and potential therapeutic target in advanced prostate cancer.
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